Ebola virus disease
23 December 2016 – An experimental Ebola vaccine was highly protective against the deadly virus in a major trial, according to results published today in The Lancet. The vaccine is the first to prevent infection from one of the most lethal known pathogens, and the findings add weight to early trial results published last year. The vaccine, called rVSV-ZEBOV, was studied in a trial involving 11 841 people in Guinea during 2015.
2016 -- Recovering from an outbreak requires getting essential health services back up and running, and addressing the weaknesses of the health system. WHO's is working with affected countries in rebuilding their health systems.
September 2016 -- Empirical and modeling studies conducted during the West African epidemic have shown that large epidemics of Ebola virus disease are preventable — a rapid response can interrupt transmission and restrict the size of outbreaks, even in densely populated cities. The critical question now is how to ensure that populations and their health services are ready for the next outbreak, wherever it may occur.
The magnitude of the 2014-2015 West Africa Ebola outbreak combined with a dearth of local and international expertise in tackling the disease necessitated training on a mass scale. Over the duration of the epidemic, WHO and partners trained more than 8,000 health professionals from over 80 nations, including the Ebola-affected countries. To better understand the impact of the trainings, WHO commissioned a review, which was conducted by an independent, external body.
Ebola virus has been detected at low levels in breast milk up to 16 months after onset of Ebola virus disease symptoms. More evidence is needed to know the precise duration and infectivity of Ebola virus persistence in breast milk. Ebola survivors who are lactating may wish to have their breast milk tested for Ebola virus by RT-PCR. Women who do not know the status of their breast milk or who were tested and for whom no Ebola virus RNA was detected should continue breastfeeding.
Rebuilding health systems
Research and development
- Clinical care for survivors of Ebola virus disease
- Surveillance strategy during Phase 3 of the Ebola response
- Recovery toolkit: Supporting countries to achieve health service resilience
- Ebola response phase 3: Framework for achieving and sustaining a resilient zero
- Infection prevention and control guidance for care of patients in health-care settings, with focus on Ebola